Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 1 patents
16 readers on Mendeley
  • Article usage
  • Citations to this article (103)

Advertisement

Research Article Free access | 10.1172/JCI113245

Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-alpha in rodents.

J S Patton, P M Peters, J McCabe, D Crase, S Hansen, A B Chen, and D Liggitt

Department of Pharmacological Sciences, Genentech, Inc., South San Francisco, California 94080.

Find articles by Patton, J. in: PubMed | Google Scholar

Department of Pharmacological Sciences, Genentech, Inc., South San Francisco, California 94080.

Find articles by Peters, P. in: PubMed | Google Scholar

Department of Pharmacological Sciences, Genentech, Inc., South San Francisco, California 94080.

Find articles by McCabe, J. in: PubMed | Google Scholar

Department of Pharmacological Sciences, Genentech, Inc., South San Francisco, California 94080.

Find articles by Crase, D. in: PubMed | Google Scholar

Department of Pharmacological Sciences, Genentech, Inc., South San Francisco, California 94080.

Find articles by Hansen, S. in: PubMed | Google Scholar

Department of Pharmacological Sciences, Genentech, Inc., South San Francisco, California 94080.

Find articles by Chen, A. in: PubMed | Google Scholar

Department of Pharmacological Sciences, Genentech, Inc., South San Francisco, California 94080.

Find articles by Liggitt, D. in: PubMed | Google Scholar

Published December 1, 1987 - More info

Published in Volume 80, Issue 6 on December 1, 1987
J Clin Invest. 1987;80(6):1587–1596. https://doi.org/10.1172/JCI113245.
© 1987 The American Society for Clinical Investigation
Published December 1, 1987 - Version history
View PDF
Abstract

Treatment of healthy rats and mice with a single intravenous injection of recombinant human tumor necrosis factor-alpha (rHuTNF-alpha) caused a dose-dependent gastrointestinal inflammation. Within 30 min gastric emptying was blocked and tissue edema occurred in the small and large intestine. In the cecum hemorrhage occurred after 4 h at doses greater than or equal to 250 micrograms/kg. The cecum exhibited an acute inflammatory response following rHuTNF-alpha treatment similar to that seen in tumor necrosis at the same dose. The vascular endothelium became swollen, increased numbers of neutrophils and other leukocytes attached to and penetrated the endothelium, and finally hemorrhage occurred. Treatment of rats with daily injections of rHuTNF-alpha (250 micrograms/kg per d) for 3 wk failed to produce cachexia. Within 24-48 h rats became resistant to the hemorrhagic effect of rHuTNF-alpha, however, the cytokine still caused a transitory block of gastric emptying after 10 d of treatment. Treatment at 5- or 10-d intervals produced results similar to the initial injection. These results suggest that maximum hemorrhagic response will occur when rHuTNF-alpha is administered at intervals of 5-10 d rather than daily.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1587
page 1587
icon of scanned page 1588
page 1588
icon of scanned page 1589
page 1589
icon of scanned page 1590
page 1590
icon of scanned page 1591
page 1591
icon of scanned page 1592
page 1592
icon of scanned page 1593
page 1593
icon of scanned page 1594
page 1594
icon of scanned page 1595
page 1595
icon of scanned page 1596
page 1596
Version history
  • Version 1 (December 1, 1987): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article (103)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
16 readers on Mendeley
See more details